Spectral–luminescent study of a hydrogel based on hyaluronic acid dialdehyde and chitosan succinate containing the Lucentis drug

Resumo

A spectral-luminescent study of the hydrogel formed by the crosslinking of chitosan succinate and hyaluronic acid dialdehyde (HAD) macromolecules, which is a dosage form of the Lucentis drug (active ingredient, ranibizumab), has been conducted. The individual fluorescence (FL) spectra of Lucentis (λ_max = 336 nm), HAD (λ_max = 328 and 438 nm), and the hydrogel (λ_max = 396 nm) have been obtained. An analysis of these spectra suggests the participation of carbonyl groups and proteins contained in HAD in its gelation with chitosan succinate. The diffusion of Lucentis from the hydrogel into a physiological solution was studied by a FL method to demonstrate the high prolonged-release properties of the new dosage form.